Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.75 |
| ▸ | CA2 | P00918 | 7/20 | 0.75 |
| ▸ | CA9 | Q16790 | 6/20 | 0.75 |
| ▸ | PLK1 | P53350 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | MAOA | P21397 | 1/20 | 0.64 |
| ▸ | MAOB | P27338 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18606715 | 0.86 | CA1 (1.00) | CA1CA2CA9PLK1ALDH1A1 | |
| SCHEMBL18606680 | 0.84 | ALDH1A1 (0.74) | CA1CA2CA9PLK1ALDH1A1 | |
| SCHEMBL5445610 | 0.84 | MAPT (0.71) | ALDH1A1KMT2AMEN1RAB9A | |
| Hydrochloric Acid SCHEMBL3717975 | 0.83 | BCAT2 (0.72) | CA1CA2CA9ALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL3717981 | 0.83 | SIRT2 (0.60) | CA1CA2CA9ALDH1A1KMT2A | |
| SCHEMBL5453541 | 0.83 | ALDH1A1 (0.79) | CA1CA2CA9ALDH1A1KMT2A | |
| SCHEMBL14095964 | 0.82 | EPHX1 (0.63) | ALDH1A1KMT2AMEN1RAB9A | |
| SCHEMBL14095975 | 0.82 | SIRT2 (0.60) | ALDH1A1KMT2AMEN1RAB9A | |
| SCHEMBL14095963 | 0.82 | ALDH1A1 (0.62) | ALDH1A1KMT2AMEN1RAB9A | |
| SCHEMBL18606704 | 0.81 | CA1 (0.76) | CA1CA2CA9PLK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-20070040151-A1 | Two-component initiator system (amine-free) with very good storage stability and particular suitability for acid systems | HERAEUS KULZER GMBH (DE) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | RNASE1, SARS1, EIF2AK2 | CA1 4355/4885CA2 3158/4885CA9 4031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.